Literature DB >> 23183378

Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.

Maria Sole Chimenti1, Eleonora Ballanti, Carlo Perricone, Paola Cipriani, Roberto Giacomelli, Roberto Perricone.   

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis. Pathogenesis is incompletely understood and pathophysiological role of synovium is just beginning to be elucidated. PsA could be considered an enthesal disease and this hypothesis is the link between mechanical stress (entheses) and immunologically active tissue (synovium). Histologically, PsA is characterized by lining layer hyperplasia, diffuse infiltrate of B, T, macrophages and dendritic cells associated with neutrophils' proliferation and angiogenesis. T cells are present, and oligoclonal T-cell expansions have been demonstrated in both skin and synovium. Histological findings are associated with monocyte-derived cytokines expression, as Myeloid-related protein (S100A8/A9). They play an important role in intracellular functions and cytoskeleton-membrane interactions. S100A8/A9 has a role in the propagation and perpetuation of the inflammatory process in patients with psoriasis and PsA, because of an activated monocyte/macrophage system that involve, distal to the skin, the "enthesal-complex." Complement system can be considered part of the acute phase response as demonstrated by higher plasma levels of C3 and C4 complement components in PsA patients compared with healthy subjects. These abnormal levels are then reverted by anti-TNF drugs. Evidences of efficacy of anti-TNF are expressed by reduction of vascularity and immune cells in synovial tissue. Therefore, innate response generates high concentrations of inflammatory cytokines which promote effector functions of a variety of tissue cells and sustain the characteristic chronicity of synovitis. The challenge will be the development of molecules affecting the balance between innate and adaptive immunity without affecting beneficial functions of the perfect concert of immunological process. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183378     DOI: 10.1016/j.autrev.2012.10.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  34 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.

Authors:  F Pica; M S Chimenti; R Gaziano; C Buè; I A Casalinuovo; P Triggianese; P Conigliaro; D Di Carlo; V Cordero; G Adorno; A Volpi; R Perricone; E Garaci
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

3.  Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing.

Authors:  Harshit Nanda; Nirmaladevi Ponnusamy; Rajasree Odumpatta; Jeyaraman Jeyakanthan; Arumugam Mohanapriya
Journal:  3 Biotech       Date:  2020-01-10       Impact factor: 2.406

4.  A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.

Authors:  Maria Sole Chimenti; Paola Triggianese; Paola Conigliaro; Marco Tonelli; Gianfranco Gigliucci; Lucia Novelli; Miriam Teoli; Roberto Perricone
Journal:  Clin Rheumatol       Date:  2017-07-31       Impact factor: 2.980

Review 5.  Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.

Authors:  Aisha Q Butt; Angela McArdle; David S Gibson; Oliver FitzGerald; Stephen R Pennington
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 6.  New treatments for inflammatory rheumatic disease.

Authors:  Carlo Selmi; Elena Generali; Marco Massarotti; Gerolamo Bianchi; Carlo A Sciré
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

7.  Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.

Authors:  Francesco Carubbi; Luigi Zugaro; Paola Cipriani; Armando Conchiglia; Lorenzo Gregori; Cristino Danniballe; Maria Letizia Pistoia; Vasiliki Liakouli; Piero Ruscitti; Francesco Ciccia; Giovanni Triolo; Carlo Masciocchi; Roberto Giacomelli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

Review 8.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  Autoimmunity diseases of the skin.

Authors:  Jozélio Freire Carvalho; Paulo Ricardo Criado; Valéria Aoki; Yehuda Shoenfeld
Journal:  Autoimmune Dis       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.